Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The Primary Objectives of this study are to determine the: • Safety and tolerability of 3 months of dosing of INCB028050 in patients with active rheumatoid arthritis who have had inadequate response to any DMARD therapy. • Efficacy of INCB028050 at 3 months in patients with active rheumatoid arthritis who have had inadequate response to any DMARD therapy.
Critère d'inclusion
- active rheumatoid arthritis